Fibrocaps significantly reduced median TTH for each indication ( p < 0.001 ) and was superior for secondary efficacy end points of restricted mean TTH ( p < 0.001 ) and probability of hemostasis at 3 ( p < 0.001 ) and 5 ( p 0.002 ) minutes .